Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 5/20 | 0.33 |
| ▸ | CCND1 | P24385 | 5/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030519 | 0.82 | KDM4E (0.38) | PRKCICDK4CCND1CCNE2CCNE1 | |
| SCHEMBL29234948 | 0.78 | ESR1 (0.34) | PRKCICDK4CCND1CYP2A6PIK3CB | |
| SCHEMBL15712762 | 0.78 | PRKCI (0.48) | PRKCICYP2A6PIK3CB | |
| SCHEMBL31276705 | 0.78 | CDK4 (0.35) | PRKCICDK4CCND1CCNE2CCNE1 | |
| SCHEMBL12536131 | 0.78 | CDK4 (0.39) | PRKCICDK4CCND1CCNE2CCNE1 | |
| SCHEMBL6029602 | 0.77 | MTNR1A (0.36) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL21725647 | 0.76 | GRM2 (0.37) | PRKCICDK4CCND1CCNE2CCNE1 | |
| SCHEMBL14745740 | 0.74 | NR3C1 (0.30) | PRKCI | |
| SCHEMBL594433 | 0.72 | CDK4 (0.36) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL21725650 | 0.72 | XDH (0.46) | PRKCICDK4CCND1CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | PRKCI 596/4885CDK4 1/4885CCND1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.